NURS 6521: Advanced Pharmacology Assignment: Pharmacotherapy for Cardiovascular Disorders Week 2 Case Assignment

Patient Factor

The patient factor I chose is to conduct factors, which centers on the AO’s obesity. Obesity is a risk factor for both hypertension and hyperlipidemia, just as different conditions, for example, diabetes that can confound treatment for cardiovascular issues. Two components influencing the pharmacokinetics for this patient incorporate helpless nourishment and diminished course. It is expected that this current patient’s sustenance is poor, as this generally goes with obesity (Burchum & Rosenthal, 2017). Decreased circulation can be influenced by restricted physical movement, vasoconstriction that goes with hypertension, and the potential for plaque development in hyperlipidemia. Understanding these danger factors just as the potential impacts they may have on the patient’s capacity to react suitably to a medicine routine and get restorative treatment, the patient should be urged to adjust their eating regimen and exercise propensities too, especially through the proposal of the DASH diet. 

Improving the Drug Therapy Plan

            There are a few regions for development in AO’s medication plan. Initially, beta-blockers are known to add to hyperlipidemia. Additionally, beta-blockers are not regularly utilized as a first-line treatment for hypertension. Getting this, the atenolol should be suspended. Since the atenolol is being ended, hydralazine should also be ceased, as it should in a perfect world be given with a beta-blocker and a diuretic. Since the suggested first line of treatment for hypertension is diuretics, a portion of 12.5 mg of hydrochlorothiazide should be started every day (Jiang & Lu, 2016).  This medication was chosen since thiazide diuretics are viewed as safe in diabetics, with a decrease in mortality from coronary illness and stroke. The dose was chosen because, however, they are viewed as sheltered and helpful; people with diabetes should be regulated thiazide diuretics at the most minimal conceivable portion. Though the patient is not a known diabetic, the person has many risk factors for the sickness, and it should be viewed as an undeniable chance that the patient either as of now has or will before long create diabetes (Quintana, Janszky, & Gigante, 2016). Simvastatin is a suitable decision for hyperlipidemia, as the statin drug class is the suggested first-line treatment and individual medication decision is directed by the cholesterol levels, which I was not given.

References

Burchum, J., & Rosenthal, L. (2017). Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants – E-Book. Elsevier Health Sciences